Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EKF Diagnostics Holdings ( (GB:EKF) ) has shared an update.
EKF Diagnostics has repurchased 400,000 of its ordinary shares at a weighted average price of 24.5 pence, with all of the shares to be cancelled rather than held in treasury. The move reduces the company’s share count to 430,503,112 voting shares, marginally enhancing existing shareholders’ ownership stakes and signalling ongoing capital management activity, while major shareholder Harwood Capital Management did not participate in this particular transaction.
The buyback was executed on 9 April 2026 in a single trade on AIM at 24.5 pence per share, in line with the company’s authorised programme. Following cancellation, the new share count provides the reference denominator for investors’ regulatory disclosure thresholds, clarifying the voting rights structure and offering greater transparency for stakeholders monitoring their holdings under UK market rules.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £26.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
Spark’s Take on EKF Stock
According to Spark, TipRanks’ AI Analyst, EKF is a Neutral.
The score is driven by solid financial resilience (low leverage and generally healthy cash generation) and a constructive earnings outlook (margin improvement, capacity expansion, new contracts, and buyback). These positives are tempered by weak technicals (price below major moving averages and negative MACD) and only mid-range valuation support (P/E ~15.6, no dividend yield provided).
To see Spark’s full report on EKF stock, click here.
More about EKF Diagnostics Holdings
EKF Diagnostics Holdings plc is an AIM-listed global diagnostics company specialising in point-of-care analysers for hematology and diabetes, as well as life sciences services that manufacture enzymes and custom products for diagnostic, food and industrial uses. Headquartered in Penarth near Cardiff, it operates five manufacturing sites in the U.S. and Germany and sells into more than 120 countries worldwide.
Average Trading Volume: 445,813
Technical Sentiment Signal: Strong Sell
Current Market Cap: £104.1M
Find detailed analytics on EKF stock on TipRanks’ Stock Analysis page.